Phaseline

Companies › AP Biosciences

AP Biosciences: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AP402
HER2-targeting immunoconjugate
ERBB2Phase 1Advanced Solid TumorDec 2026
AP203–Phase 1Locally Advanced or Metastatic Solid TumorsDec 2026
AP601
Bispecific antibody targeting CD73
CD73Phase 1Solid TumoursDec 2027
AP505
Anti-PD-L1 and Anti-VEGF antibody fusion protein
CD274, VEGFAPhase 1Advanced Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06723964AP505Phase 1Advanced Solid TumorsOncologyOct 2024
NCT06669975AP402Phase 1Advanced Solid TumorOncologyDec 2026
NCT05473156AP203Phase 1Locally Advanced or Metastatic Solid TumorsOncologyDec 2026
NCT07165067AP601Phase 1Solid TumoursOncologyDec 2027

Targets

CD73 (1) ERBB2 (1) CD274 (1) VEGFA (1)

Companies with the same targets

Roche Beijing Biotech AstraZeneca Suzhou Suncadia Biopharmaceuticals Pfizer Shanghai Henlius Biotech Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Sichuan Baili Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.